Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

Lung cancer expert Triparna Sen delivered a seminar in the Cancer Biology Seminar Series at the University of Wisconsin Jan.

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

and AbbVie is looking specifically at this group in a phase 1 study that is looking at the combination of Teliso-V and AstraZeneca's EGFR inhibitor Tagrisso (osimertinib), to see if the ADC can ...

The HER3-directed ADC will be tested in patients whose disease had progressed despite earlier treatment with EGFR inhibitors, including third-generation drugs like AZ's Tagrisso (osimertinib).

In England, about 600 people will benefit from the daily pill that helps treat lung cancer as it becomes routinely available on the NHS.